SCHEMBL10036077

SCHEMBL10036077

CC1=NN(c2ccccc2)C(=O)/C1=C\C=C\C=C\c1c(C)nn(-c2ccccc2)c1O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 14/20 0.58
KMT2A Q03164 11/20 0.58
ALDH1A1 P00352 10/20 0.58
MAPK1 P28482 8/20 0.58
L3MBTL1 Q9Y468 7/20 0.58
TDP1 Q9NUW8 5/20 0.58
HTT P42858 4/20 0.58
POLB P06746 4/20 0.58
LMNA P02545 2/20 0.58
MEN1 O00255 9/20 0.57
KDM4E B2RXH2 4/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
PKM P14618 3/20 0.57
OPRK1 P41145 2/20 0.57
GAA P10253 2/20 0.57
RECQL P46063 1/20 0.57
MMP14 P50281 1/20 0.57
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA9 Q16790 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22314650 0.96 MAPT (0.63) MAPTKMT2AALDH1A1MAPK1L3MBTL1
SCHEMBL22313966 0.96 MAPT (0.63) MAPTKMT2AALDH1A1MAPK1L3MBTL1
SCHEMBL22289103 0.96 MAPT (0.63) MAPTKMT2AALDH1A1MAPK1L3MBTL1
SCHEMBL13943138 0.96 MAPT (0.63) MAPTKMT2AALDH1A1MAPK1L3MBTL1
SCHEMBL12715277 0.93 MAPT (0.54) MAPTKMT2AALDH1A1MAPK1L3MBTL1
SCHEMBL12522409 0.90 KAT8 (0.51) MAPTKMT2AALDH1A1MAPK1L3MBTL1
SCHEMBL14508083 0.90 KAT8 (0.51) MAPTKMT2AALDH1A1MAPK1L3MBTL1
SCHEMBL278669 0.90 KAT8 (0.51) MAPTKMT2AALDH1A1MAPK1L3MBTL1
SCHEMBL14129428 0.89 MAPT (0.55) MAPTKMT2AALDH1A1MAPK1L3MBTL1
SCHEMBL13763582 0.88 KAT8 (0.48) MAPTKMT2AALDH1A1MAPK1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120035187-A1 ANTI-NEURODEGENERATIVE DISEASE AGENT KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) 2012-02-09 US disclosed
US-20120035187-A1 ANTI-NEURODEGENERATIVE DISEASE AGENT KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) 2012-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035187-A1 ANTI-NEURODEGENERATIVE DISEASE AGENT SNCA, PSEN1, CDR2 MAPT 43/4885KMT2A 2624/4885ALDH1A1 2810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.